



Colibri Heart Valve Concludes Patient Enrollment in First-in-Human Study of Proprietary TAVI System in Dominican Republic

- Findings to be Presented at Upcoming 25th Annual Transcatheter Cardiovascular Therapeutics Scientific Conference -

BROOMFIELD, CO – October 24, 2013 – [Colibri Heart Valve, LLC](#), a privately held medical device company, announced that patient enrollment has concluded in the first-in-human study of the Company's transcatheter aortic valve implantation (TAVI) system in the Dominican Republic trial site. Analysis of the data from patients enrolled in this site yielded clinical outcomes that met the study's endpoints. Colibri will provide a clinical update on the first-in-human study at the 25th Annual Transcatheter Cardiovascular Therapeutics (TCT) Conference taking place in San Francisco October 27 – November 1, 2013. The [Colibri TAVI system](#) (US Patent 8,361,144) is the world's first and only low profile, 14 French pre-mounted, pre-crimped, and pre-packaged, ready-for-use TAVI system.

“We have observed a preserved aortic valve area (AVA) of 2.0 to 2.3 cm² in these patients, which is atypically high for TAVI devices. This suggests that the Colibri proprietary valve design may improve valve performance, which in turn could potentially improve clinical benefit,” stated Dr. Pedro Ureña, primary investigator of the Colibri clinical study and director of the cardiovascular department at the Center of Advanced Medicine (CEDIMAT) in Santo Domingo, Dominican Republic

[Joseph B. Horn](#), Colibri's president and chief executive officer added, “The proprietary folded valve design of the Colibri valve maximizes functionality while minimizing profile and has produced impressive clinical results to date. We are looking forward to the next phase of development, in which we expect to commence a study by the end of 2014 to support a CE Mark application.”

Colibri will have two presentations at the upcoming 25th Annual TCT Conference, the first being Dr. Bernard Chevalier's podium presentation titled “The Colibri TAVR System.” This presentation is part of the “Aortic Valve Therapies: Today and Tomorrow: Part II” session on Monday, October 28 that begins at 8:00am local time. Dr. Chevalier's presentation will begin at 4:23pm. Dr. Chevalier is an attending cardiologist at the Institut Cardiovasculaire Paris-Sud and a member of the Colibri scientific advisory board.

In addition, Dr. David Paniagua will be presenting “First Human Transcatheter Aortic Valve Implantation of the Colibri Heart Valve, a Pre-mounted, Pre-packaged, Low Profile Ready for Use, Dry Valve in a 14 French Delivery System; Six Months Follow up” in the oral abstract session taking place on Tuesday, October 29 at 2:57pm. Dr. Paniagua is a co-founder of Colibri and an assistant professor of medicine in the Baylor College of Medicine Section of Cardiology.

For more information on the first-in-human implantation, please visit the Colibri Heart Valve booth (#1139) during the [TCT 2013](#) meeting.

About the Colibri Heart Valve and the Ready-to-Use Colibri TAVI System

Colibri Heart Valve, LLC is a privately held medical device company based in Broomfield, CO that researches and develops novel heart valve technologies. Colibri has developed a pre-mounted, pre-crimped, and pre-packaged, ready-for-use transcatheter aortic valve implantation (TAVI) device called the “[Colibri TAVI System](#).” TAVI is an important treatment option for heart valve replacement due to its minimally invasive nature, clinical efficacy, extensive patient experience, and reduced procedural costs. Colibri’s advanced technology is a culmination of over 10 years of research and development by Colibri’s founders, Dr. David Paniagua and Dr. R. David Fish into the tissue, valve design, frame, and delivery catheter. Colibri’s unique tissue processing method produces extremely strong, durable, and biocompatible tissue. The proprietary tissue enables loading, crimping, and packaging of the Colibri valve at manufacture, making in-procedure valve rinsing and loading at time of use unnecessary. The “Colibri TAVI System” is designed to be shipped ready-for-use.

Colibri’s corporate headquarters and pre-commercialization facilities are located in Broomfield, Colorado with R&D located in Houston, Texas. For more information, visit: www.colibrihv.com.

Corporate and Media Relations Contact:

Eric Schauble, VP, Corporate Development
Colibri Heart Valve, LLC
Telephone: (303) 460-8667
eschauble@colibrihv.com

Aline Schimmel
Scienta Communications
Telephone: (312) 238-8957
aschimmel@scientapr.com